Carfilzomib, sold under the brand name Kyprolis, is an anti-cancer medication acting as a selective proteasome inhibitor. Chemically, it is a tetrapeptide...
19 KB (1,730 words) - 05:43, 7 April 2024
lenalidomide or pomalidomide), and a proteasome inhibitor (e.g., or bortezomib, carfilzomib or ixazomib), in combination with a steroid (e.g., dexamethasone). While...
131 KB (13,506 words) - 14:34, 29 September 2024
parent compound of multiple myeloma drug carfilzomib (Kyprolis). Based on successful Phase II trials of carfilzomib, Onyx Pharmaceuticals acquired Proteolix...
31 KB (2,873 words) - 05:59, 14 July 2024
ixabepilone which is an analogue of the natural product epothilone B and carfilzomib which is derived from epoxomicin and eravacycline derived from tetracycline...
6 KB (619 words) - 19:44, 27 October 2022
product candidate, carfilzomib (PR-171), is a tetrapeptide epoxyketone for treating multiple myeloma, a blood cancer. The drug carfilzomib works by preventing...
3 KB (284 words) - 12:35, 29 June 2024
Parkinson's-like symptoms in rats. Derivatives of epoxomicin include carfilzomib. Epoxomicin, Santa Cruz Biotechnology Meng, L; Mohan, R; Kwok, BH; Elofsson...
4 KB (327 words) - 09:07, 28 August 2021
(Abemaciclib Alvocidib† Palbociclib Ribociclib Seliciclib†) PrI Bortezomib Carfilzomib Oprozomib Ixazomib PhI (Anagrelide) IMPDI (Tiazofurin§) LI (Masoprocol)...
11 KB (734 words) - 02:39, 12 October 2024
(Abemaciclib Alvocidib† Palbociclib Ribociclib Seliciclib†) PrI Bortezomib Carfilzomib Oprozomib Ixazomib PhI (Anagrelide) IMPDI (Tiazofurin§) LI (Masoprocol)...
31 KB (2,908 words) - 06:38, 22 September 2024
(Abemaciclib Alvocidib† Palbociclib Ribociclib Seliciclib†) PrI Bortezomib Carfilzomib Oprozomib Ixazomib PhI (Anagrelide) IMPDI (Tiazofurin§) LI (Masoprocol)...
36 KB (3,336 words) - 06:38, 17 October 2024
and a proteasome inhibitor. It is also indicated in combination with carfilzomib and dexamethasone, for the treatment of adults with relapsed or refractory...
31 KB (3,186 words) - 02:41, 16 July 2024